DKA Capital (formerly Dansk Kapitalanlæg) is a well-established Danish PE fund investing in and developing knowledge-intensive growth
Business Model:
Revenue: $0
Employees: 0-0
Address: Havnegade 39
City: Copenhagen
State: zealand
Zip: DK-1058
Country: DK
DKA Capital (formerly Dansk Kapitalanlæg) is a well-established Danish PE fund investing in and developing knowledge-intensive growth companies with a global potential with the aim of creating long term sustainable value. Since DKA Capital was founded in 1984, we have completed 180 investments and 175 exits of which 21 were in the form of IPO&s;s (Initial Public Offerings). This makes us one of the largest and most experienced investors in Denmark. The specialisation process in DKA Capital was initiated in 2006 and in 2011 the management of DKA Capital together Norwegian Argentum acquired 75% of the fund DKA II. DKA Capital has through DKA II 5 companies in its portfolio. DKA II is owned by the management of DKA Capital, Argentum, Nordea Liv &a; Pension and Danica Pension. We believe in direct and constructive communication leaving no doubt to what DKA Capital stands for or what we would like to achieve during our period of ownership. Together with the companies we execute professionally and create sense-of-urgency. DKA Capital&s;s aim is to be strategic and intelligent change of ownership. And we want to maintain our position as one of the most credible partners for knowledge-intensive growth companies. We invest in knowledge intensive companies with international growth opportunities. During the recent years we have marked ourselves as one of Denmark&s;s leading funds within this field.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/1997 | Acadia Pharmaceuticals Inc. | Series A | 6M |
5/2005 | NsGene | Venture Round | 0 |
10/2010 | Secunia | Venture Round | - |
8/1997 | Acadia Pharmaceuticals Inc. | Series B | 0 |
5/2000 | HepaVec AG | Series A | 0 |
8/1998 | Acadia Pharmaceuticals Inc. | Series D | 0 |
1/2021 | CanopyLAB | Debt Financing | 0 |
4/2001 | Develogen AG | Series B | 0 |
6/2000 | Acadia Pharmaceuticals Inc. | Debt Financing | 0 |
1/2007 | Hymite | Series B | 11.5M |
7/2002 | Direct Conversion | Series B | 21M |
1/2021 | CanopyLAB | Debt Financing | 0 |
10/2010 | Secunia | Venture Round | - |
1/2007 | Hymite | Series B | 0 |
5/2005 | NsGene | Venture Round | 0 |
7/2002 | Direct Conversion | Series B | 0 |
4/2001 | Develogen AG | Series B | 0 |
6/2000 | Acadia Pharmaceuticals Inc. | Debt Financing | 0 |
5/2000 | HepaVec AG | Series A | 0 |
8/1998 | Acadia Pharmaceuticals Inc. | Series D | 0 |
8/1997 | Acadia Pharmaceuticals Inc. | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|